Drug Profile
Research programme: sexual dysfunction therapy - Palatin Technologies
Alternative Names: PL-6983Latest Information Update: 06 Dec 2021
Price :
$50
*
At a glance
- Originator Palatin Technologies
- Class Peptides
- Mechanism of Action Melanocortin type 1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Erectile dysfunction; Female sexual dysfunction
Most Recent Events
- 30 Nov 2021 Palatin Technologies receives patent allowance for method of treating cytokine storm using melanocortin-specific peptide in USA in November 2021
- 04 Nov 2017 No recent reports of development identified for preclinical development in Erectile-dysfunction in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Female-sexual-dysfunction in USA